PPIDT00470
Drug Information
| Name | Ansuvimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB16385 |
| Type | biotech |
| Indication | Ansuvimab is indicated for the treatment of _Zaire ebolavirus_ infection in adult and pediatric patients, including neonates born to a mother who tests positive for _Zaire ebolavirus_ by RT-PCR.[L29560] Ansuvimab has not been shown to be effective against other species within the _Ebolavirus_ and _Marburgvirus_ genera; factors such as the possible emergence of resistant strains suggest local information on circulating _Zaire ebolavirus_ strains should be consulted before initiating treatment.[L29560] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
400 mg/8mL
|